Who Should Not Take Bioidentical Hormones

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery

Key Takeaways

• Bioidentical hormone replacement therapy (BHRT) has clear contraindications for people with estrogen-dependent cancers, cardiovascular events, clotting disorders, liver disease, and late post-menopausal initiation.

• Late initiation of BHRT (after age 60 or more than 10 years post-menopause) carries elevated cardiovascular and clotting risks.

• Compounded bioidentical hormones lack FDA regulation, which creates variability in purity and potency and can heighten risk for patients with existing health issues.

• Supervised peptide protocols such as the Glow Stack, NAD, and Selank provide non-hormonal options that work through signaling pathways rather than direct hormone replacement.

• Individuals interested in personalized, lab-informed peptide therapy can schedule a consultation at Mirror Plastic Surgery to explore alternatives matched to their health profile.

Primary Contraindications to Bioidentical Hormones at a Glance

The following conditions represent absolute or strong relative contraindications to BHRT, based on ACOG clinical guidance on hormone therapy for menopause.

• Personal history of breast cancer or estrogen-dependent cancer

• History of endometrial cancer

• Prior stroke or heart attack

• History of blood clots (deep vein thrombosis, pulmonary embolism)

• Active or chronic liver disease

• Undiagnosed vaginal bleeding

• Current pregnancy

• Age over 60 or more than 10 years post-menopause without prior hormone use

These categories are drawn from ACOG clinical guidance on hormone therapy for menopause.

Why Some Patients Are Not Candidates for Bioidentical Hormones

These contraindications reflect quantified clinical risks, particularly for estrogen-sensitive cancers and cardiovascular events. The estrogen-sensitive nature of certain cancers is a central concern. Studies associate systemic HRT with a higher risk of recurrence in women diagnosed with hormone receptor-positive breast cancer.

Compounded bioidentical hormones are not regulated by the FDA and can vary in strength and purity. A “bioidentical” label does not guarantee safety, especially for people with elevated cancer or cardiovascular risk. This regulatory gap increases concern for patients who already carry higher-risk profiles.

For individuals excluded from BHRT on these grounds, non-hormonal peptide protocols can address overlapping concerns. The Glow Stack, which combines GHK-Cu, BPC-157, and TB500, targets systemic inflammation, collagen and elastin decline, and soft tissue repair. BPC-157 and TB-500 accelerate recovery, reduce inflammation, and support tissue regeneration, making them relevant for age-related decline and inflammatory symptoms. These peptides act upstream of the endocrine system and signal repair without introducing external hormones.

Age, Timing, and When Hormone Replacement Becomes Higher Risk

Age and timing of initiation are clinically significant variables in BHRT safety. Combined hormone therapy has been associated with increased risk of heart attack for older women, with risk related to age, existing medical conditions, and timing of initiation. Some research suggests protection against heart attacks when therapy starts within 10 years of menopause in women younger than 60, with potentially greater benefit for estrogen-only therapy.

Women who are over 60 or more than 10 years post-menopause and have not previously used hormone therapy face a less favorable risk-benefit calculation. Cardiovascular and clotting risks increase with the duration of the hormonal gap. Initiation at this stage becomes a more complex clinical decision that often requires consideration of non-hormonal options.

For this population, NAD (Nicotinamide Adenine Dinucleotide) and Selank offer non-hormonal alternatives. NAD+ injections assist in cellular energy production and DNA repair, and patients often report improved mental clarity and reduced brain fog within weeks.¹ Selank acts on anxiety pathways similar to benzodiazepines but without the dependency component, which helps address mood and cognitive symptoms that frequently accompany late-stage hormonal decline.

Additional Medical Contraindications and Peptide Alternatives

Clotting Disorders

A history of blood clots is a contraindication to systemic hormone therapy. Estrogen increases hepatic production of clotting factors and elevates thrombotic risk in individuals with inherited or acquired coagulation disorders. For these patients, KPV, a gut-targeted anti-inflammatory peptide, addresses the systemic inflammatory burden that often accompanies clotting-related conditions without any thrombogenic mechanism.

Liver Disease

The liver metabolizes exogenous hormones. Active or chronic hepatic disease impairs this process and can lead to hormone accumulation and toxicity. Liver disease is a condition for which systemic hormone therapy is usually not recommended. Peptides such as BPC-157 act through receptor-mediated pathways distinct from hepatic hormone metabolism and offer a structurally different option for individuals with compromised liver function.

Cardiovascular Disease

Beyond the timing-related cardiovascular risks discussed earlier, individuals with established cardiovascular disease or prior heart attack face additional contraindications to BHRT regardless of age. Peptide therapy may deliver more stable daytime energy, improved mitochondrial function, reduced oxidative stress, and more restorative sleep for patients experiencing age-related fatigue.¹ These outcomes support cardiovascular wellness without hormonal exposure.

Undiagnosed Bleeding and Pregnancy

Undiagnosed vaginal bleeding requires evaluation before any hormonal intervention, because BHRT could mask or worsen an underlying pathology. Pregnancy is an absolute contraindication to BHRT. Peptide therapy may not be appropriate during pregnancy or breastfeeding, in individuals with active malignancy, or when certain endocrine conditions are not yet stabilized. This reinforces that peptide protocols also require individualized clinical screening.

BHRT Risks vs. Peptide Benefits: A Side-by-Side View

The following table summarizes how specific BHRT contraindications relate to peptide alternatives and highlights the different risk profiles for patients who cannot use hormone therapy.

Risk Factor	BHRT Risk	Peptide Benefit	Source
Hormone receptor-positive cancer history	Increased recurrence risk with systemic HRT	GHK-Cu supports collagen signaling without hormonal receptor activity	Breast Cancer Org
Age >60 / >10 years post-menopause	Increased cardiovascular risk with late initiation	NAD targets mitochondrial energy production, Selank addresses anxiety without hormonal pathways	ACOG; EmpowerMed
Clotting or liver disorder	Estrogen elevates clotting factors and strains impaired hepatic metabolism	KPV reduces gut and systemic inflammation via non-thrombogenic pathways	ACOG
Regulatory and quality variability	Compounded BHRT can vary in purity and potency	Supervised peptide protocols sourced from batch-tested compounding pharmacies under practitioner oversight

Meet Your Practitioner: Ellie Pranckevicius, FNP-BC

Peptide protocols at Mirror Plastic Surgery are led by Ellie Pranckevicius, FNP-BC, a board-certified Family Nurse Practitioner. Ellie holds a Bachelor’s in Health Science from Boston University, completed an aesthetics licensure program, and earned both her Bachelor’s and Master’s in Nursing from the University of South Florida. She spent four years in the Neuroscience ICU at Tampa General Hospital, where she developed clinical depth in physiology, metabolic health, and complex patient management.

Her career began at a high-end medical spa in Boston, which gave her a dual foundation in skin physiology and advanced clinical science that she now applies directly to peptide protocol design. Every patient receives a comprehensive consultation that may include lab panels, a full medical history review, and ongoing concierge support, including direct text access and telemedicine availability across the United States.

Schedule your peptide assessment with Ellie to receive lab-informed protocol design and personalized support.

Decision-Making Considerations for Peptide Therapy

Beyond practitioner credentials, individuals evaluating peptide therapy as a BHRT alternative should understand the practical factors that determine protocol safety and success. First, comprehensive lab evaluation, including thyroid, liver, kidney, metabolic, and hormone panels, establishes a baseline and identifies root causes rather than treating symptoms in isolation. This baseline informs sourcing decisions, because many peptides are prescribed through compounding pharmacies and used off-label, which makes quality verification essential when protocols are tailored to specific lab findings.

Many peptides are prescribed through compounding pharmacies and used off-label, and while not all peptides are individually FDA-approved as branded drugs, their use under medical supervision follows established safety and prescribing standards. Even with quality sourcing and personalized dosing, outcome variability remains real. Genetics, lifestyle, and protocol adherence all influence results, so expectations about timelines should stay realistic.

Early benefits such as more stable energy and improved sleep may appear in weeks 2–4, with metabolic and body-composition changes typically noticeable at 6–12 weeks and sustained vitality emerging beyond 3 months.¹ Maintenance protocols are usually required to sustain outcomes, which aligns with how most ongoing wellness regimens function.

Common Misconceptions About Peptides

“Peptides are only for weight loss.” GLP-class peptides have received significant public attention for weight management, but the peptide category is substantially broader. Consider the range of non-weight-related mechanisms. GHK-Cu targets collagen and elastin production for skin and tissue health. BPC-157 and TB500 address musculoskeletal and systemic inflammation for recovery and pain management.

NAD supports mitochondrial energy for cognitive function and overall vitality. KPV targets gut inflammation for digestive health. Selank addresses anxiety through nootropic pathways for mood regulation. Each operates through distinct mechanisms unrelated to weight and addresses diverse health concerns that often accompany hormonal decline.

“Peptides are the same as hormones.” Peptide therapy signals the body to produce more of its own growth hormone or improve metabolic function without direct replacement, whereas BHRT introduces exogenous hormones. This distinction is clinically meaningful for individuals with contraindications to hormonal exposure.

“Unsupervised peptide use carries the same risk as supervised protocols.” The primary risk of unsupervised peptide use involves lack of third-party quality testing, no individualized dosing, and no screening for pre-existing conditions or drug interactions. Medical supervision addresses each of these variables and reduces preventable complications.

Conclusion: Choosing Between BHRT and Peptide Therapy

Bioidentical hormone replacement therapy carries well-documented contraindications for individuals with histories of estrogen-dependent cancers, cardiovascular events, clotting disorders, liver disease, and for those initiating therapy late in the post-menopausal window. These contraindications reflect quantified clinical risks supported by ACOG, breast cancer outcome data, and FDA guidance. For individuals in these categories, supervised peptide protocols offer a structurally different mechanism by working upstream through signaling pathways rather than hormonal replacement, with protocols tailored to individual lab results and health histories.

Informed, individualized decision-making grounded in lab data and practitioner oversight remains the standard that separates safe outcomes from avoidable harm. Discuss your eligibility for peptide therapy at Mirror Plastic Surgery to determine whether a supervised protocol aligns with your health profile and goals.

Frequently Asked Questions

Can I use bioidentical hormones if I had breast cancer years ago?

A personal history of breast cancer, particularly hormone receptor-positive breast cancer, is a primary contraindication to systemic BHRT. Women with this history who took systemic HRT may have a higher risk of recurrence compared to those who did not. Some oncologists may discuss low-dose vaginal estrogen for urogenital symptoms in specific cases, but this requires individualized evaluation with an oncologist. Non-hormonal peptide protocols such as the Glow Stack can address collagen decline, inflammation, and skin health without engaging estrogen receptor pathways.

Is there an age at which hormone replacement becomes too risky to start?

Clinical guidance identifies women over 60 or more than 10 years post-menopause as a higher-risk group for initiating systemic hormone therapy, particularly regarding cardiovascular outcomes. The risk-benefit calculation shifts unfavorably the longer the hormonal gap persists before initiation. For women in this window, non-hormonal options including NAD for mitochondrial energy support and Selank for anxiety and cognitive clarity offer alternatives that do not carry the same cardiovascular risk profile.

Are peptides regulated by the FDA?

As noted in the decision-making section, most peptides operate in a distinct regulatory space from FDA-approved branded drugs. The FDA has approved non-hormonal therapies for menopausal symptoms, but many wellness peptides are prescribed through compounding pharmacies under off-label use. The primary safety concern involves obtaining products from unregulated sources without medical supervision. Mirror Plastic Surgery sources peptides from providers with rigorous batch testing and provides full clinical oversight, including lab panels and ongoing monitoring, to reduce the risks associated with unverified products.

How long does it take to see results from peptide therapy?

Timeline varies by peptide and individual physiology. Early benefits such as improved energy, better sleep quality, and reduced cravings may appear within weeks 2–4 of starting a protocol. Metabolic and body-composition changes are typically noticeable at 6–12 weeks. Sustained outcomes, including collagen improvements, inflammatory reduction, and vitality, generally emerge beyond 3 months of consistent use.¹

Results are not uniform across individuals. Genetics, lifestyle, diet, and protocol adherence all influence outcomes, which is why lab-informed personalization sits at the center of Mirror Plastic Surgery’s approach.¹

What happens if I stop taking peptides?

Stopping peptide therapy usually leads to a gradual return to baseline for the conditions being managed. Inflammation that was being modulated will likely return to its prior state, and collagen signaling support will diminish over time. This pattern mirrors most ongoing wellness or medical regimens, where benefits are sustained by continued use.

Maintenance protocols are designed to support long-term outcomes and are adjusted based on evolving lab results and patient response, rather than following a fixed, one-size-fits-all schedule.